OSI Seeks Partner For DPP-4 Inhibitor Paused At Phase III Gate

OSI’s metabolic business unit Prosidion also aims to out-license its glucokinase activator candidate in the next three months, Prosidion president tells “The Pink Sheet” DAILY.